Grail, Inc. (NASDAQ:GRAL - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $23.71 and last traded at $23.21, with a volume of 300071 shares traded. The stock had previously closed at $22.16.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the company. Guggenheim started coverage on Grail in a report on Thursday, October 17th. They set a "neutral" rating for the company. Morgan Stanley began coverage on Grail in a research note on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 target price for the company. Finally, Wolfe Research initiated coverage on shares of Grail in a research report on Friday, November 15th. They set a "peer perform" rating on the stock.
Read Our Latest Research Report on GRAL
Grail Stock Performance
The firm's fifty day moving average is $15.86.
Insider Activity
In other Grail news, major shareholder Chun R. Ding bought 7,629 shares of the company's stock in a transaction on Tuesday, October 1st. The stock was bought at an average price of $13.52 per share, for a total transaction of $103,144.08. Following the transaction, the insider now owns 3,503,655 shares of the company's stock, valued at approximately $47,369,415.60. The trade was a 0.22 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Aaron Freidin sold 30,452 shares of the firm's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $14.02, for a total value of $426,937.04. Following the completion of the transaction, the chief financial officer now owns 268,277 shares in the company, valued at $3,761,243.54. This represents a 10.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders bought 58,829 shares of company stock valued at $757,298.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Recommended Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
